NexMed Announces the Ability of the NexACT® Technology to Deliver Drugs Orally and with Enhanced Bioavailability
January 12 2010 - 1:51PM
Business Wire
NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of
products based on the NexACT® technology, today announced that
pre-clinical results from its research and development group at
Bio-Quant successfully demonstrated the ability of the NexACT
technology to deliver an oral formulation of Taxol® (paclitaxel)
and to enhance the drug’s bioavailability by approximately ten-fold
through this oral administration. Taxol, a first line chemotherapy
drug used to treat breast, lung and ovarian cancers, is currently
administered through an intravenous infusion that can take up to 24
hours to complete.
Dr. Bassam Damaj, NexMed’s Chief Executive Officer stated, “The
results from these proof of concept studies are exciting and
support our belief that NexACT can be successfully used to enhance
oral bioavailability of a broad range of drugs, which could include
our proprietary drug candidates, generic drugs and proprietary
drugs owned by others who are developing second-generation
formulations to provide extended patent protection with increased
convenience and bioavailability. Our ability to leverage our
proprietary NexACT technology in this way is expected to provide
exciting new development opportunities and will no longer restrict
us to the topical delivery of dermal drugs. Additional studies are
ongoing to extend the validation of the technology into other
classes of oral drugs.”
About NexMed
NexMed, due to its recent acquisition of Bio-Quant, is the
largest specialty contract research organization (“CRO”) based in
San Diego, CA and is one of the industry’s most experienced CROs
for in vitro and in vivo pharmacology services and research models.
NexMed has a proprietary product pipeline based on its NexACT drug
delivery technology, including a late stage terbinafine treatment
for onychomycosis, a late stage alprostadil treatment for erectile
dysfunction, a Phase 2 alprostadil treatment for female sexual
arousal disorder, and an early stage treatment for psoriasis and
wound healing. For further information, go to www.nexmed.com and
www.bio-quant.com.
Taxol® is a registered trademark of Bristol-Myers Squibb
Company.
Forward-Looking Statement Safe
Harbor
Statements under the Private Securities Litigation Reform Act:
with the exception of the historical information contained in this
release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may
individually or mutually impact the matters herein described for a
variety of reasons that are outside the control of the Company. For
example, and without limitation, there can be no assurance that the
Company will be able to achieve or will continue to pursue its
product development goals, that initial pre-clinical findings will
be supported by later studies, or that the Company will be able to
integrate its business following the Bio-Quant acquisition in a
successful manner.
Nexmed (MM) (NASDAQ:NEXM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nexmed (MM) (NASDAQ:NEXM)
Historical Stock Chart
From Apr 2023 to Apr 2024